Antara Banerjee

Company: Takeda Pharmaceutical

Job title: Senior Director, Head Immune Cell Engager Therapies

Seminars:

ADT3: A Potential First-In-Class EGFR X Vδ1 Bispecific Engager for In Situ Activation of Vδ1 Γδ T Cells And Enhanced Cytotoxicity Towards Solid Tumors 9:30 am

ADT3 is a bispecific engager that is designed to activate tissue resident VD1 T cells ADT3 activates VD1 Gamma delta T cells via crosslinking through EGFR on tumor cells resulting in proliferation, activation and tumor cell killing Activation of VD1 cells via ADT3 enables activated Vd1 cells to recognize and kill EGFR positive and EGFR…Read more

day: Conference Day Two